JACOBIO PHARMACEUTICALS

jacobio-pharmaceuticals-logo

Jacobio Pharmaceuticals, founded in 2015 in Beijing China, is a clinical-stage biotech company dedicated to the development of global truly innovative drugs for the unmet needs in China and abroad. The vision and mission of Jacobio have become a global leader to provide revolutionary therapies for serious and life-threatening diseases such as cancer, autoimmune and infectious diseases. Jacobio is founded by seasoned executives from top global and local pharmaceuticals companies who have an asto... unding track record of success and backed by prestigious venture capital firms such as Lilly Asia Ventures and Qiming Capitals. Dr. Yinxiang Wang, the co-founder and chairman of Jacobio, also is one of the founders of Betta Pharmaceuticals, an A-share listed innovative pharmaceutical company, and the national "The Recruitment Program of Global Experts". The most senior management team has over 20 years of drug R&D experience and successfully brought several innovative drugs into the clinical and market stage. Within 3 years, Jacobio has quickly established a compelling drug R&D team of over 100 employees and one-stop capability covering target discovery, med-chemistry, pharmacology, CMC formulation, clinical, and registration. With those, the company has built up a rich pipeline of 8-10 assets with clear competitive advantages and excellent drug properties. JAB-3068, the most advanced program for Jacobio, has focused on a novel target potential for both immunotherapy and target therapy and enter Phase I clinical trial in US and IND approved at China and clinical trials would be initiate at China very soon.

#SimilarOrganizations #People #Financial #More

JACOBIO PHARMACEUTICALS

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2015-01-01

Status:
Active

Contact:
+86 010-56315466

Email Addresses:
[email protected]

Total Funding:
101.55 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Domain Not Resolving Mobile Non Scaleable Content Nginx IPv6 PHP PHP 7 FLoC Opt-Out


Similar Organizations

canbridge-pharmaceuticals-logo

CANbridge Pharmaceuticals

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .

newbridge-pharmaceuticals-logo

NewBridge Pharmaceuticals

Newbridge Pharmaceuticals is a pharmaceutical and medical device company engaged in developing oncology and supportive care products.

salix-pharmaceuticals-logo

Salix Pharmaceuticals

Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.


Current Advisors List

nisa-leung_image

Nisa Leung Board Member @ Jacobio Pharmaceuticals
Board_member
2017-03-14

Current Employees Featured

yinxiang-wang_image

Yinxiang Wang
Yinxiang Wang CEO and Chairman @ Jacobio Pharmaceuticals
CEO and Chairman

Founder


yinxiang-wang_image

Yinxiang Wang

Investors List

abbvie-biotech-ventures_image

AbbVie Biotech Ventures

AbbVie Biotech Ventures investment in Venture Round - Jacobio Pharmaceuticals

qiming-venture-partners_image

Qiming Venture Partners

Qiming Venture Partners investment in Series C - Jacobio Pharmaceuticals

qiming-venture-partners_image

Qiming Venture Partners

Qiming Venture Partners investment in Series C - Jacobio Pharmaceuticals

hillhouse-capital_image

Hillhouse Capital Group

Hillhouse Capital Group investment in Series C - Jacobio Pharmaceuticals

prudence-investment-management_image

Prudence Investment Management

Prudence Investment Management investment in Series C - Jacobio Pharmaceuticals

qiming-venture-partners_image

Qiming Venture Partners

Qiming Venture Partners investment in Venture Round - Jacobio Pharmaceuticals

lilly-asia-ventures_image

Lilly Asia Ventures

Lilly Asia Ventures investment in Series B - Jacobio Pharmaceuticals

qiming-venture-partners_image

Qiming Venture Partners

Qiming Venture Partners investment in Series B - Jacobio Pharmaceuticals

Investments List

Date Company Article Money raised
2021-08-31 HebeCell Jacobio Pharmaceuticals investment in Series A - HebeCell 53 M USD

More informations about "Jacobio Pharmaceuticals"

Jacobio Pharma|以患者受益为导向

加科思药业(1167.hk)致力于为患者提供突破性治疗方案。公司在研项目围绕kras、肿瘤免疫、肿瘤代谢、p53、rb、myc六大肿瘤信号通路布局,核心项目以全球前三为目标。公司的愿景是与合作伙伴携手共进,成为全球认可的药物研发领导 …See details»

Jacobio Pharmaceuticals - Crunchbase Investor Profile …

Jacobio Pharmaceuticals, founded in 2015 in Beijing China, is a clinical-stage biotech company dedicated to the development of global truly innovative …See details»

Jacobio Pharma - LinkedIn

Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six ...See details»

Jacobio Pharmaceuticals - Funding, Financials, Valuation & Investors

Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company focusing on the development of innovative oncology and other therapies. New. Resources. ... How much …See details»

JACOBIO-B (1167.HK) Company Profile & Facts - Yahoo Finance

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company's drug development …See details»

Partners - Jacobio Pharma

In the relay race that is anti-tumor drug R&D, all participants need to leverage their strengths and collaborate Jacobio focuses on independent R&D of innovative drugs to bring breakthrough …See details»

Jacobio Pharmaceuticals Group Co Ltd, 1167:HKG profile - FT.com

Mar 20, 2025 Jacobio Pharmaceuticals Group Co Ltd is an investment holding company mainly engaged in the research and development of new drugs at the clinical stage. The Company is …See details»

Wang Yinxiang – Chairman & CEO, Jacobio

Aug 4, 2024 Partnering with Jacobio Pharmaceuticals offers a unique opportunity to collaborate on groundbreaking initiatives that have the potential to shape the future of medicine. Reflecting on international relations, back in …See details»

Jacobio Company Profile - Office Locations, Competitors ... - Craft

Jacobio has 5 employees across 5 locations and ¥63.52 m in annual revenue in FY 2023. See insights on Jacobio including office locations, competitors, revenue, financials, executives, …See details»

1167.HK | Jacobio Pharmaceuticals Group Co. Ltd. Company Profile ...

Company profile for Jacobio Pharmaceuticals Group Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates. View detailed 1167.HK description & …See details»

www.jacobio.com

Www.jacobio.comSee details»

Jacobio Pharmaceuticals Group sees highest filings and grants …

The European Patent Office(EPO), United States(US), South Korea(KR), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where …See details»

Jacobio Pharmaceuticals, AbbVie partner on cancer drugs

Jun 2, 2020 Jacobio has designed its early clinical-stage SHP2 assets, JAB-3068 and JAB-3312, to selectively inhibit SHP2 activity.. Jacobio Pharmaceuticals CEO and chairman …See details»

Jacobio Pharmaceuticals Group Co., Ltd. (JBPHF) - Yahoo Finance

Find the latest Jacobio Pharmaceuticals Group Co., Ltd. (JBPHF) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»

Jacobio Pharmaceuticals Announces 2021 Interim Results

Sep 1, 2021 Beijing and Boston, Aug. 31 2021 -- Jacobio Pharmaceuticals (“Jacobio”, 1167.HK) announced its results for the first half of 2021. Investment in R&D for the clinical-stage biotech …See details»

AbbVie pens cancer pact with U.S.-China biotech Jacobio

Jun 1, 2020 AbbVie has signed a new pact to focus on SHP2 inhibitors, which target a key node in cancer and immune cells, from early-stage biotech Jacobio Pharmaceuticals. | AbbVie has …See details»

Jacobio Pharma Announces 2024 Annual Results - PR Newswire

Mar 19, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. ... Pharmaceuticals. …See details»

Jacobio Pharmaceuticals Reveals Promising Cancer Therapy Data

Jun 2, 2024 Jacobio Pharmaceuticals has recently showcased promising clinical data at the 2024 ASCO Annual Meeting, indicating significant treatment efficacy of its novel combination …See details»

JACOBIO-B (1167.HK)

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company's drug development …See details»

Jacobio Pharmaceuticals Gains EU Orphan Drug Status

Oct 21, 2024 Jacobio Pharmaceuticals has announced that its KRAS G12C inhibitor, Glecirasib, has received orphan drug designation from the European Medicines Agency for treating …See details»

linkstock.net © 2022. All rights reserved